VINCENNES, Ind. (WTWO/WAWV)— Good Samaritan announced the acquisition of a new state-of-the-art robotic-assisted platform for minimally invasive lung biopsies.
The name of this new platform is the Ion Endoluminal System. The technology will help with both precision and access while diagnosing lung nodules. This could then be used to detect and treat lung cancer earlier in patients.
According to the news release, lung cancer is still the leading cause of cancer-related deaths, though early detection can significantly improve survival rates. This new system is made by the same group that created the da Vinci Surgical System. The system will allow doctors to navigate deep into the lungs of a patient with increased stability and precision. The system will also allow tissue sampling from hard-to-reach nodules with less invasive procedures.
“With the introduction of Ion, we can provide our patients with a more advanced and minimally invasive approach to lung biopsy,” said Good Samaritan Pulmonologist Johnathon Grant, DO. “This means greater accuracy, faster results, and ultimately, better outcomes for those at risk of lung cancer.”
The technology is said to be able to complete more successful biopsies with less complications. Patients can learn more about this new technology at this link.
Comments